glycine has been researched along with Febrile Neutropenia in 1 studies
Febrile Neutropenia: Fever accompanied by a significant reduction in the number of NEUTROPHILS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Montesinos, P | 1 |
| Recher, C | 1 |
| Vives, S | 1 |
| Zarzycka, E | 1 |
| Wang, J | 1 |
| Bertani, G | 1 |
| Heuser, M | 1 |
| Calado, RT | 1 |
| Schuh, AC | 1 |
| Yeh, SP | 1 |
| Daigle, SR | 1 |
| Hui, J | 1 |
| Pandya, SS | 1 |
| Gianolio, DA | 1 |
| de Botton, S | 1 |
| Döhner, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation[NCT03173248] | Phase 3 | 146 participants (Actual) | Interventional | 2017-06-26 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
EFS was defined as the time from randomization until treatment failure, relapse from remission, or death from any cause, whichever occurs first. Treatment failure was defined as failure to achieve complete remission (CR) by Week 24. CR: Bone marrow blasts <5% and no Auer rods; absence of extramedullary disease; Absolute neutrophil count (ANC) ≥1.0 × 10^9 per litre (10^9/L) (1000 per microlitre [1000/μL]); platelet count ≥100 × 10^9/L (100,000/μL); independence of red blood cell transfusions. Participants who had an EFS event (relapse or death) after, 2 or more missing disease assessments were censored at the last adequate disease assessment documenting no relapse before the missing assessments. The reported data represents the Kaplan-Meier median value. (NCT03173248)
Timeframe: Up to Week 24
| Intervention | months (Median) |
|---|---|
| AG-120 + Azacitidine | 0.03 |
| Placebo + Azacitidine | 0.03 |
1 trial available for glycine and Febrile Neutropenia
| Article | Year |
|---|---|
Ivosidenib and Azacitidine in
Topics: Antineoplastic Agents; Azacitidine; Febrile Neutropenia; Glycine; Humans; Isocitrate Dehydrogenase; | 2022 |